Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch Investment case Allergy Therapeutics PLC Investment case Overview At a glance Financial highlights Investment case Business model Strategy Regulatory news Email alert Results, reports and presentations Financial Calendar Share tools Shareholder services AIM Rule 26 Corporate governance Investor and Advisor Contacts Solid revenue stream from European business driven by Innovative, convenient and patient friendly (short course) products Focused investment across the business, reflective in performance Strength of broad portfolio with Modified Mite and venom SCIT Best in class commercial and sales teams 10% CAGR growth over the 19 years since the Company formed Strong pipeline Highly positive results achieved from Grass Phase II trial Modified Mite: Short course product with global potential Positive results achieved from pre-clinical peanut SCIT product (Peanut represents a new opportunity into the $8billion worldwide food allergy market) Preparing for US Entry $2billion estimated allergy immunotherapy market $300 – 400 million estimated peak grass sales No registered injectable products in the US Portfolio of products offer a strategic advantage to capture US market Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor Cookie Control

Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch Overview Allergy Therapeutics PLC Overview We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Our vaccines are aluminium free. Driving convenience; our ultra-short course treatments make life easier and increase adherence. Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease. We are a proud and passionate team of scientists and business specialists with a vision that delivers growth and transforms the way we think about immunology. Discover more with Allergy Therapeutics Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor Cookie Control